By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
Figs' stock price is reacting to a significant slowdown in growth, with a 29% drop despite beating earnings estimates. The market is concerned about the company's ability to maintain its premium valuation as growth decelerates from 28% to a projected 14-16% by 2026.
Risk: The sharp deceleration in growth and the high valuation (73.5x P/E) make the stock vulnerable to multiple compression if growth slows further.
Opportunity: Despite the growth concerns, Figs' strong balance sheet (cash-rich, debt-free) and high gross margins (70%) could make it an attractive acquisition target or provide downside protection if growth stalls.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Figs beat on sales and beat on earnings last night. Today, it sold off anyway.
Guidance calls for Q1 sales growth to slow dramatically later in the year.
Pull out the crash cart -- Figs (NYSE: FIGS) is on life support.
The popular purveyor of medical and surgical scrubs and other apparel took a huge tumble on Friday, crashing 29.4% through 10:40 a.m. ET despite beating analyst forecasts for both sales and earnings last night.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Heading into its Q1 report, analysts forecast Figs to earn $0.01 per share on $152.5 million in sales. Figs actually earned $0.03 per share and reported sales of $159.9 million.
So good news, right? Investors should be happy? Except they aren't -- and guidance seems to be the reason.
In Q1, Figs grew sales a strong 28%, with scrubwear sales up 27% and non-scrubwear up an even better 31%. Figs improved its gross profit margin (albeit only by 0.1%). It grew operating costs slower than sales (up only 23%). Figs even flipped from a small net loss a year ago, to $0.03 in profits this time -- an earnings growth rate of infinity!
But when it came time to give guidance, the most Figs would promise for 2026 was sales growth of 14% to 16%.
I get why investors are spooked. Figs grew 28% in Q1, but promised barely half that growth over the course of the rest of the year -- but here's the thing:
Wall Street is only expecting Figs to grow its sales by 12% this year. Investors may be upset that 14% is less than 28%, sure. But it's also comfortably ahead of 12%, and that means Figs just promised to beat earnings this year.
That sounds like good news to me. If it were a lot cheaper than its current 73.5 price-to-earnings ratio, I might even buy Figs stock.
Before you buy stock in Figs, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Figs wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $475,926! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,296,608!
Now, it’s worth noting Stock Advisor’s total average return is 981% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 8, 2026. *
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Figs' valuation multiple is fundamentally incompatible with a mid-teens growth trajectory, necessitating a further contraction in its forward P/E ratio."
The market's visceral reaction to Figs isn't just about the 14-16% growth guidance; it's a fundamental re-rating of a 'growth' stock that is losing its premium status. Trading at a 73.5x P/E ratio is unsustainable when top-line growth is decelerating by nearly 50% year-over-year. Investors are rightfully punishing the company for failing to scale operating leverage effectively. While the article highlights a beat on current earnings, it ignores the reality that Figs is transitioning from a high-growth disruptor to a standard apparel retailer. At this valuation, the stock is priced for perfection, and any sign of slowing momentum triggers an immediate exit for institutional holders.
If Figs can maintain its 70%+ gross margins while successfully expanding into non-scrub categories, the current sell-off may represent an overreaction to conservative guidance that the company is sandbagging to beat later.
"At 73.5x P/E, FIGS' deceleration from 28% Q1 growth to 14-16% FY2026 guidance justifies multiple compression to 20-30x, implying 60%+ downside."
FIGS (NYSE: FIGS) tumbled 29.4% despite Q1 EPS of $0.03 beating $0.01 estimates and sales of $159.9M topping $152.5M forecasts, with 28% YoY revenue growth (scrubs +27%, non-scrubs +31%). Yet FY2026 guidance of 14-16% sales growth—above Street's 12%—signals sharp deceleration from Q1 momentum, triggering the selloff at a lofty 73.5 P/E (likely trailing, post-profitability inflection). Gross margins edged up just 0.1%, opex rose 23% (better than sales but no big leverage), and the article omits competitive pressures in commoditized medical apparel plus healthcare staffing slowdowns post-COVID hiring boom. Risk: normalization crushes premium valuation.
FIGS flipped to profitability with 'infinite' EPS growth YoY and guidance still beats consensus by 2-4 points, suggesting upside surprise potential and room for re-rating if Q2 confirms margin stability.
"A 28%-to-15% deceleration mid-year, not the absolute guidance beat, is what the market is pricing—and at current multiples, that's a legitimate repricing event."
The article frames this as irrational panic, but the 29% crash signals something real: deceleration anxiety. Yes, 14-16% guidance beats consensus at 12%, but that's a *floor* promise, not upside. The real issue: Q1's 28% growth collapsing to ~15% midyear implies Q2-Q4 comps are materially weaker—possibly single digits by year-end. At 73.5x forward P/E, FIGS is priced for sustained 20%+ growth. If guidance implies a growth cliff, the multiple compression is justified. The article's math (beating 12% = good) ignores that investors extrapolate *trends*, not absolute numbers.
If Q1's 28% was inflated by pent-up demand or one-time factors, then 14-16% full-year is actually normalized sustainable growth—and at that rate, 73.5x P/E is genuinely expensive but not absurd for a high-margin apparel brand with secular tailwinds in medical fashion.
"The strongest risk to the bull case is that Figs’ 2026 guide implies meaningful growth deceleration, which could drive multiple compression and earnings disappointment unless margins or market share surprise to compensate."
Q1 was solid (sales $159.9m, +28%; EPS $0.03) but the 14-16% 2026 sales growth guide signals a material deceleration from the quarter’s pace and from the market’s hopes. The stock’s 29% intraday drop suggests investors fear the growth punch is fading and that margins or SG&A leverage may not expand enough to justify the current multiple (about 73.5x forward P/E). The article glosses over whether Figs can sustain non-scrubwear momentum, manage cost levels, or defend hospital/contract-based demand. A sustained beat versus the guidance would be needed to justify any meaningful re-rating; otherwise, multiple compression risks ahead.
The selloff may already reflect the deceleration risk; even with a Q1 beat, 14-16% growth might still disappoint, especially if costs rise or market share stalls, keeping the multiple under pressure.
"The market is ignoring the floor provided by FIGS' debt-free balance sheet and high gross margins, making it an attractive target for acquisition at current valuation levels."
Claude, you’re hitting on the 'growth cliff,' but everyone is ignoring the balance sheet. FIGS holds ~$150M in cash and zero debt. While you focus on P/E compression, the market is pricing this like a distressed retailer, not a debt-free brand with 70% gross margins. Even if growth decelerates to 15%, the enterprise value-to-sales ratio is approaching a level where a private equity buyout or strategic acquisition becomes the floor for this stock.
"FIGS' premium valuation and meager FCF yield undermine the buyout floor despite pristine balance sheet."
Gemini, strong balance sheet noted, but $150M cash/no debt doesn't guarantee a buyout floor at 73.5x P/E amid growth cliff to 15%. PE firms target distressed assets or FCF machines—FIGS projects ~1% FCF yield on current EV/Sales (1.8x), too puny for activists. Unmentioned risk: idle cash invites pressure for value-destructive deals or dilution, eroding the 'floor' thesis.
"FIGS' balance sheet strength inverts the risk calculus—the downside is capped by cash accumulation, not the upside by multiple compression alone."
Grok's FCF yield critique is sharp, but misses the optionality angle. At 1.8x EV/Sales with 70% gross margins, FIGS generates real cash even at 15% growth. The floor isn't a buyout multiple—it's intrinsic value. If management deploys that $150M into buybacks at 73.5x P/E, that's destructive. But if they hold cash and let FCF accrue, the stock becomes a bond proxy with equity upside. The market's panic assumes management incompetence; that's the real bet here.
"Cash isn't a reliable buyout floor at 73.5x; with decelerating growth, buybacks at these prices would destroy value rather than unlock it."
Grok's cash-is-a-floor angle is plausible, but treating $150M cash as a buyout anchor at 73.5x is flawed. Private markets rarely pay a perpetual premium for a growth deceleration story, and 1% FCF on the EV/Sales still implies scant downside protection if growth stalls. The bigger risk is margin/leverage and customer concentration in hospital channels, not simply idle cash inviting 'value deals.' A buyback at these prices would be a misallocation.
Figs' stock price is reacting to a significant slowdown in growth, with a 29% drop despite beating earnings estimates. The market is concerned about the company's ability to maintain its premium valuation as growth decelerates from 28% to a projected 14-16% by 2026.
Despite the growth concerns, Figs' strong balance sheet (cash-rich, debt-free) and high gross margins (70%) could make it an attractive acquisition target or provide downside protection if growth stalls.
The sharp deceleration in growth and the high valuation (73.5x P/E) make the stock vulnerable to multiple compression if growth slows further.